License, Collaboration and Service Agreements (Tables)

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of remaining potential milestone payments

Remaining potential payments are milestone and royalty based, and are as follows (in millions):

Event	Milestone payments (up to)
GSK's submission of a new drug application with the FDA for tebipenem HBr	$25.0
Total potential commercial milestone payments based on first sale (US/EU)	$150.0
Total potential sales milestone payments	$225.0
Royalties	Low-single digit to low-double digit (if sales exceed $1.0 billion) tiered royalties on net product sales